Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГУ Московский НИИ психиатрии Минздравсоцразвития РФ
Список исп. литературыСкрыть список 1. Вертоградова О.П., Поляков С.Э., Степанов И.Л. и др. Распространенность и характеристика аффективных расстройств, выявленных при эпидемиологическом исследовании лиц работоспособного возраста. В кн.: Ранняя диагностика и прогноз депрессий. М.: МНИИП, 1990; с. 5–15. 2. Abelson JL. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991; 48: 157–62. 3. Akiskal HS. Toward a definition of generalized anxiety disorder as an anxious temperament type. Acta Psychiatr Scand 1998; 98 (Suppl. 3): 66–73. 4. American Psychiatric Association DSM-V Development, 2010, dsm5.org 5. Andlin-Sobocki P, Wittchen H. Cost of anxiety disorders in Europe. Eur J Neurol 2005; 12 (Suppl.): 39–44. 6. Angst J, Vollrath M. The natural history of anxiety disorders. Acta Psychiatr Scand 1991; 84: 446–52. 7. Angst J, Gamma A, Baldwin DS et al. The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci 2009; 259 (1): 37–45. 8. Angst J, Gamma A, Bienvenu JO et al. Varying temporal criteria for generalized anxiety disorder: prevalence and clinical characteristics in a young age cohort. Psychol Med 2006; 36 (9): 1283–92. 9. Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001; 62 (Suppl. 11): 53–8. 10. Blazer DG, Hughes D, George L et al. Generalized anxiety disorder. In Robins, Regier eds. Psychiatric disorders in America. NY: The Free Press 1991: 180–203. 11. Bleakle S. Anxiety disorders – the pharmacological management. Hospital Pharmacist 2006; 13: 119–22. 12. Boden JM, Fergusson DM, Horwood L. Anxiety disorders and suicidal behaviors in adolescence and young adulthood: findings from a longitudinal study. Psychol Med 2007; 62: 1249–57. 13. Britton N, Southreland S, Van Uden E et al. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacol 1997; 132: 6–13. 14. Bruce SE, Yonkers KA, Otto MW et al. Influence of psychiatric comorbidity on recovery and recurrence of GAD. Am J Psychiatry 2005; 162: 1179–87. 15. Bystritsky A, Kerwin L, Feusner JD et al. A pilot controlled trial of bupropion versus escitalopram in GAD. Psychophamacol Bull 2008; 41 (1): 46–51. 16. Carter C, Maddock R. Chest pain in generalized anxiety disorder. Int J Psychiatr 1992; 22: 291–8. 17. Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatr 2009; 70 (2): 25–31. 18. Davidson JR, Zhang W, Connor KM. A psychopharmacological treatment algorithm for generalized anxiety disorder (GAD). J Psychopharmacol 2010; 24: 3. 19. Drugan RC, Skolnick P, Paul S et al. A pretest procedure reliably predicts performance in models of inescapable stress. Pharmacol Biochem Behav 1989; 33: 649–54. 20. Feltner et al. Long term efficacy of pregabalin in generalized anxiety disorder. Inter Clin Phsychopharmacol 2008; 23 (1): 18–28. 21. Ferrarese C, Appolonio I, Frigo M et al. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients. Acta Psychiatr Scand 1990; 82: 69–173. 22. Fischler B, Cluydts R, De Gucht V et al. Generalized anxiety disorder in chronic fatigue syndrome. Acta Psychiatr Scand 1997; 95: 405–13. 23. Gambi F, DeBerardis D. Mirtazapine treatment of GAD: a fixed dose, open label study. J Psychopharmacol 2005; 19 (5): 483–7. 24. Garvey MJ, Noyes R, Woodman C et al. Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanillymandelic acid. Psychiatry Res 1995; 57: 1–5. 25. Goodman WK, Bose A, Wang O. Treatment of GAD with escitalopram: pooled resulys J Affect Dis 2005; 87 (2–3): 161–7. 26. Grant BF, Hasin DS, Stinson FS et al. Prevalence, correlates, comorbidity and comparative disability of DSM-IV GAD in the USA: results from the National Comorbidity Survey Psychol Med 2005; 35 (12): 747–59. 27. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Therapy 1999; 82: 1–61.28. Harter M, Conway KP, Merinkangas KR. Associations between anxiety disorders and physical illness. Eur Arch Psychiatry Clin Neurosci 2003; 253: 313–20. 29. Hedges DW, Reimherr FW, Strong RE et al. An open trial of nefazadone in adult patients with GAD. Psychopharmacol Bull 1996; 32 (4): 671–6. 30. Hindmarch I, Dawson J, Stanley N. Evaluation of the cognitive and psychomotor profile of pregabalin compared to alprazolam in normal volunteers. Int J Neuropsychopharmacol 2002; 5 (1): 241. 31. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alpazolam and placebo. Sleep 2005; 28: 187–93. 32. Ноffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depres anxiety 2006; 10: 1–19. 33. Hunt C, Slade T, Andrews G. GAD and major depression comorbidity in the National Survey. Depres Anxiety 2004; 20 (1): 23–31. 34. Jetty PV, Charney DS, Goodard AW. Neurobiology of generalized anxiety disorder. Psychiatr Clin North Am 2001; 24: 75–98. 35. Judd LL, Kessler RC, Paulus MP et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study. Acta Psych Scand 1998; 98 (Suppl. 393): 6–11. 36. Kasper et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24: 87–96. 37. Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006; 16 (Suppl. 2): 128–133. 38. Kennedy B, Schwab J. Utilization of medical specialists by anxiety disorders patients. Psychosomatics 1997; 38: 109–112. 39. Kennedy JL, Bradwein J, Koszicky D et al. Investigation of cholecystokinin system genes in anxiety disorders. Mol Psychiatr 1999; 4: 284–5. 40. Kessler RC, Brandeburg N, Lane M et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from National Comorbidity Survey Replication. Psycol Med 2005; 35: 1073–82. 41. Kessler RC, DuPont RL, Berglund A et al. Impairment in pure and comorbid GAD and major depression at 12 months in two national surveys. Am J Psychiatr 1999; 156: 1915–23. 42. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 2001; 24: 19–39. 43. Kessler RC, Chiu WT, Demler O et al. Prevalence, severity and comorbidity of 12-month DSM-IV disorders in NCSR. Arch Gen Psychiatr 2005; 62: 617–27. 44. Khan A, Farfel GM, Brock JD. Efficacy and safety of pregabalin for the treatment of GAD in elderly patients. Ann Meeting of APA, Toronto 2006; 283–4. 45. Koponen H, Allgulander C, Erickson et al. Efficacy of duloxetine for the treatment of anxiety disorder: implication for primary care. Prim Care Comp. J Clin Psychiatry 2007; 9 (2): 100–7. 46. Krasucki C, Howarf R, Mann A. The relationship between anxiety disorders and age. Int J Geriatr Psychiatry 1998; 13 (2): 79–99. 47. Kroenke K, Spilzer RL, Williams JB et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity and detection. Ann Intern Med 2007; 146: 317–25. 48. Koob GF. Corticotropin-relesing factor, norepinephrine and stress. Biol Psychiatr 1999; 46: 1167–80. 49. Lenze EJ, Mulsant BH, Shear MK et al. Efficacy and tolerability of citalopram in the treatment of late life anxiety disorders. Am J Psychiatry 2005; 162 (1): 146–50. 50. Leon AC, Olfson M, Broadhead WE et al. Prevalence of mental disorders in primary care: implication for screening. Arch Fam Med 1995; 4: 857–61. 51. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005; 15 (4): 445–52. 52. Llorca PM, Spadone C, Sol O et al. Efficacy and safety of hydroxyzine in the treatment of GAD. J Clin Psychiatr 2002; 63 (11): 1020–27. 53. Lowe B, Decker O, Muller S et al. Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care 2008; 46 (3): 266–74. 54. Lydiard B, Bielsky R, Tobias K. The efficacy of pregabalin in treating psychic and somatic symptoms in GAD. Eur Neuropsychopharmacol 2003; 13 (4): 377. 55. Lydiard RB. Neuropeptides and anxiety: focus on cholecystokinin. Clin Chem 1994; 40: 315–18. 56. Mendlewicz J, Papadimitriou G, Wimotte J. Family study of panic disorder: comparison to generalized anxiety disorder, major depression and normal subjects. Psychiatry Genetic 1993; 3: 73–8. 57. Montgomery SA. Pregabalin for the treatment of GAD. Expert Opin Pharmacother 2006; 7 (15): 2139–54. 58. Montgomery SA, Tobias K, Zornberg GL et al. Efficacy and safety of pregabalin in the treatment of GAD: a 6-week multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67 (5): 771–82. 59. Montgomery et al. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol 2009; 24: 214–22. 60. Munjack DJ, Baltazar PL, DeQuattro V et al. Generalized anxiety disorder: some biochemical aspects. Psychiatry Res 1990; 32: 35–43. 61. Noyes R, Clarkson C, Crowe RR et al. A family study of generalized anxiety disorder. Am J Psychiatry 1987; 144: 1019–24. 62. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 2001; 62 (Suppl. 11): 22–7. 63. Olfson M, Fireman B, Weissman MM et al. Mental disorders and disability among patients in primary care group practice. Am J Psychiatry 1997; 154: 1734–40. 64. Owen RT. Pregabalin: its efficacy, safety and tolerability profile in GAD. Drugs Today 2007; 43 (9): 601–10. 65. Pande AC, Crocatt JG, Feltner DE et al. Pregabalin in GAD: a placebo-controlled study. Am J Psychiatry 2003; 160 (3): 533–40. 66. Pandina GJ, Canuso CM, Turkoz I et al. Adjunctive risperidone in the treatment of GAD. Psychopharmacol Bull 2007; 40 (3): 41–57. 67. Pohl RB, Feltner DE, Fieve RR et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151–8. 68. Pollack MH, Simon NM, Zalta AK. Olanzapine augmentation of fluoxetine for refractory GAD: a placebo controlled study. Biol Psychiatry 2006; 59 (3): 211–15. 69. Rickels K, Downing R, Schweizer E et al. Antidepressants in the treatment of GAD: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50 (11): 884–95. 70. Rickels K, Wiseman K, Norstad N et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43 (12): 81–6. 71. Rickels et al. Pregabalin for the treatment of generalized anxiety disorder. A four week, double-blind, multi-center, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022–30. 72. Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation and course. J Clin Psychiatry 2009; 70 (Suppl. 2): 4–9. 73. Robert LS, Kurt K, Wiliams JBW et al. A brief measure for assembling generalized anxiety disorder. Arh Intern Med 2006; 166: 1092–97. 74. Rocca P, Beoni A, Eva C et al. Peripheral benzodiazepine receptor messenger RNA in GAD. Biol Psychiatry 1998; 43: 81–6. 75. Rocca P, Fonzo V, Scotta M et al. Paroxetine efficacy in the treatment of GAD. Acta Psychiatr Scand 1997; 95 (5): 444–50. 76. Rodrogues BF, Weisberg RB, Pagano ME et al. Characteristics and predictors of full and partial recovery from GAD in primary care patients. J Nerv Ment Dis 2006; 194 (2): 91–7. 77. Rogers MP, White K, Warshaw MG et al. Prevalence of medical illness in patients with anxiety disorders. Int J Psychiatr Med 1994; 24: 83–96. 78. Pollack MH, Zaninelly R, Goddard A et al. Paroxetine in the treatment of generalized anxiety disorder. J Clin Psychiatr 2001; 62 (5): 350–7. 79. Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry 2004; 65 (Suppl. 13): 20–6. 80. Rubio G, Lopes-Ibor JJ. Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatr Scand 2007; 115: 342–59. 81. Rynn M, Russell J, Erickson J et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder. Depres Anxiety 2008; 25 (3): 182–9. 82. Sanderson K, Andrews G. Prevalence and severity of mental health-related disability and relation to diagnosis. Psychiatr Serv 2002; 53 (1): 80–6. 83. Sareen J, Cox BJ, Affifi T et al. Anxiety disorders and risk of suicidal ideation and suicide attemps: a population based, longitudinal study of adults. Arch Gen Psychiatr 2005; 62: 1249–57. 84. Skre I, Onstad S, Evardsen J et al. A family study of generalized anxiety disorder: familial transmission and relationship to mood disorder. Acta Psychiatr Scand 1994; 90: 366–74. 85. Skre I, Onstad S, Torgersen S et al. A twin study of DSM-IIIR anxiety disorder. Acta Psychiatr Scand 1993; 88: 85–92. 86. Smith W, Targum S, Feltner DE et al. Pregabalin in GAD: long term efficacy and relapse prevention. Eur Neuropsychopharmacol 2002; 12 (Suppl. 3): 350. 87. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory GAD. J Clin Psychopharmacol 2005; 25 (5): 497–8. 88. Spitzer R, Kroenke K, Williams J et al. A brief measure for assessing generalized anxiety disorder. Arch Int Med 2006; 166: 1092–7. 89. Stahl SM. Anticonvulsants as anxiolytics: Part 2 Pregabalin and gabapentin as alpha2delta ligands at voltage gated calcium channels. J Clin Psychiatry 2004; 65: 460–1. 90. Stein MB, Heimberg RG. Well-being and life satisfaction in GAD: comparison to major depressive disorder in a community sample. J Affect Dis 2004; 79: 161–6. 91. Taylor CP. The biology and pharmacology of calcium channel proteins. CNS Drug Rev 2004; 10: 183–8. 92. Taylor DP, Eison MS, Riblet LA et al. Pharmacological and clinical effects of buspirone. Pharmacol Biochem Bahav 1985; 23: 687–94. 93. Terrie E, HonaLee H, Avshalom C et al. Depression and generalized anxiety disorder: cumulative and sequental comorbidity in a Birth cohort followed prospectively to age 32 years. Arch Gen Psychiatry 2007; 64 (6): 651–60. 94. Ustun TB, Sartorius N. Mental illness in general health care. An International Study. WHO, Wiley&Sons, 1995. 95. Van Praag HM. Anxiety and increased aggression as pacemakers of depression. Acta Psychiatr Scand 1998; 98 (Suppl. 393): 81–8. 96. Wang PS, Berglund P, Kessler RC. Recent care of common mental disorders in the United States. J Gen Intern Med 2000; 15 (5): 284–92. 97. Wise MG, Taylor SE. Anxiety and mood disorders in medically ill patients. J Clin Psychiatry 1990; 51 (1): 27–32. 98. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-IIIR generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355–64. 99. Wittchen HU. Recognition and management of anxiety symptoms. Brit J Psychiatr 1998; 173 (Suppl. 34): 1–3. 100. Wittchen HU. Generalized anxiety disorder: prevalence, burden and cost to society. Depress Anxiety 2002; 16 (4): 162–71. 101. Wittchen HU. Generalized anxiety disorder – a risk factor for depression? Int J Met Psych Res 2006; 10 (1): 52–7. 102. Wittchen HU, Carter RM, Pfister H et al. Disabilities and quality of life in pure and comorbid GAD and major depression in a national survey. Int Clin Psychopharmacol 2000; 15: 319–28. 103. Wu JC. Buchsbaum MS, Hershey TG et al. PET in generalized anxiety disorder. Biol Psychiatry 1991; 29: 1181–9. 104. Yonkers KA, Dyck IR, Warshaw M et al. Factors predicting the clinical course of GAD. Br J Psychiatr 2000; 176: 544–9. 105. Yonkers KA, Bruce SE, Dyck IR et al. Chronicity, relapse and illness: course of panic disorder, social phobia and GAD. Depres Anxiety 2003; 17 (3): 173–9.